ApiJect
ApiJect offers a platform that integrates Blow-Fill-Seal (BFS) technology with connectable components for prefilled drug delivery systems, and provides licensing and support to pharmaceutical companies and CDMOs.
Services
ApiJect provides licensing and support services to pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) for the efficient fill-finish of injection drug products. These services help integrate Blow-Fill-Seal (BFS) aseptic drug packaging with connectable components, creating prefilled drug delivery systems. ApiJect also offers proprietary temperature management methods in the BFS processes, potentially enabling the fill-finish of temperature-sensitive biologics and vaccines.
Technology Development Center
ApiJect operates a Technology Development Center in Orlando, Florida. This center focuses on advancing BFS technology and supporting pharmaceutical companies with drug delivery challenges. The center plays a critical role in the research and development of new methodologies and technologies to further improve the efficiency and effectiveness of BFS aseptic drug packaging systems.
Innovation Recognition
ApiJect has been recognized for its technology and innovation in the field of drug delivery solutions. The company was named a Top 10 Drug Delivery Solutions Provider in both 2022 and 2023. This recognition reflects ApiJect's commitment to advancing drug delivery technologies and its impact on the pharmaceutical industry.
K-1 Auto-Disabled Syringe
In 2023, ApiJect celebrated the 40th anniversary of the invention of the K-1 Auto-Disabled Syringe. This device has been credited with saving over 20 million lives by preventing syringe reuse, a critical factor in reducing the spread of infectious diseases. The K-1 Auto-Disabled Syringe represents a significant milestone in medical device innovation and public health safety.